Arbeitsgruppe Molekulare Psychiatrie (Prof. Dr. Thomas Bayer)

UNIVERSITÄTSMEDIZIN GÖTTINGEN, Klinik für Psychiatrie und Psychotherapie

Intellectual property activities

Monoclonal antibodies targeting amyloid beta pyroglutamate Abeta 3-42 oligomers: The monoclonal antibodies  selectively recognize oligomeric  pyroglutamate Abeta 3-42. and works in a preclinical model for Alzheimer's diseaseUS patent granted August 5, 2014 and EU patent granted April 27, 2016.

Mouse model for sporadic Alzheimer's disease: The transgenic mice express Abeta 4-42 and develop a massive CA1 pyramidal neuron loss in the hippocampus correlating well with age-dependent spatial reference memory deficits. US patent granted December 8, 2015.

Conformational specific antibodies against Abeta 1-42, pyroglutamate 3-42 and 4-42 oligomers:  Passive immunization with the antibodies rescue memory deficits in preclinical Alzheimer models, reduce plaque load and neuron loss in the hippocampus.  US patent granted April 11, 2017.